Juha Rinne
jurin@utu.fi +358 50 441 2400 |
Publications
- Alterations in type 2 dopamine receptors across neuropsychiatric conditions: A large-scale PET cohort (2024)
- NeuroImage: Clinical
(Refereed journal article or data article (A1)) - Cognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET (2024)
- Neurobiology of Disease
(Refereed journal article or data article (A1)) - Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA (2024)
- EJNMMI Research
(Refereed journal article or data article (A1)) - Kinetic Modeling of Brain [18-F]FDG Positron Emission Tomography Time Activity Curves with Input Function Recovery (IR) Method (2024)
- Metabolites
(Refereed journal article or data article (A1)) - Midlife insulin resistance, APOE genotype, and change in late-life brain beta-amyloid accumulation : A 5-year follow-up [11C]PIB-PET study (2024)
- Neurobiology of Disease
(Refereed journal article or data article (A1)) - Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals (2024)
- Frontiers in Neurology
(Refereed journal article or data article (A1)) - Adenosine A2A receptor availability in cerebral gray and white matter of patients with Parkinson's disease (2023)
- Parkinsonism and Related Disorders
(Refereed journal article or data article (A1)) - Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson’s disease (2023)
- Journal of Neurology
(Refereed journal article or data article (A1)) - APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly (2023)
- Alzheimer's Research and Therapy
(Refereed journal article or data article (A1)) - Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3) (2023)
- Nature Medicine
(Other (O2)) - Bone marrow metabolism is affected by body weight and response to exercise training varies according to anatomical location (2023)
- Diabetes, Obesity and Metabolism
(Refereed journal article or data article (A1)) - Effect of xenon on brain injury, neurological outcome, and survival in patients after aneurysmal subarachnoid hemorrhage-study protocol for a randomized clinical trial (2023)
- Trials
(Refereed journal article or data article (A1)) - Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes (2023)
- Alzheimer's and Dementia
(Refereed journal article or data article (A1)) - Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease (2023)
- Neurobiology of Disease
(Refereed journal article or data article (A1)) - Impaired Early Insulin Response to Glucose Load Predicts Episodic Memory Decline: A 10-Year Population-Based Cohort Follow-Up of 45-74-Year-Old Men and Women (2023)
- Journal of Alzheimer's Disease
(Refereed journal article or data article (A1)) - Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly (2023)
- Journal of Cerebral Blood Flow and Metabolism
(Refereed journal article or data article (A1)) - Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial (2023)
- Movement Disorders
(Refereed journal article or data article (A1)) - Quantification of the purinergic P2X(7) receptor with [C-11]SMW139 improves through correction for brain-penetrating radiometabolites (2023)
- Journal of Cerebral Blood Flow and Metabolism
(Refereed journal article or data article (A1)) - Quantitative Perfusion Imaging with Total-Body PET (2023)
- Journal of Nuclear Medicine
(Refereed review article in scientific journal (A2)) - Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (2023)
- Nature Medicine
(Refereed journal article or data article (A1))